Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia
NCT04964505 · Brian Jonas · PHASE1 · terminated · last registry update 2026-02-23 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision” | Open Targets' class: business administrative | Registry record, Brian Jonas |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SELE in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-05Results posted on the registry: National Cancer Institute (NCI), Cytarabine + Fludarabine (NCT05146739)
- 2026-01-21Results posted on the registry: National Cancer Institute (NCI), Cytarabine + Daunorubicin (NCT03701308)
- 2025-10-20Results posted on the registry: M.D. Anderson Cancer Center, Cladribine + Cytarabine (NCT04848974)
- 2025-06-27Also stopped (terminated): Apollomics Inc., Uproleselan + Placebo (NCT05054543)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision